Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01810016
Title NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ludwig Institute for Cancer Research
Age Groups: adult
Covered Countries USA | AUS

No variant requirements are available.